In general, patients from families with a dense history of AMD and patients with severe disease at an early age were tested because those patients were expected to have a higher chance of carrying rare variants in complement genes.6,7,13,14,15,28,29 Nevertheless, the high percentage of patients with EODM carrying rare CFH variants is remarkable in comparison with the percentage (7.7%) of patients in the AMD group and with patients with EODM carrying rare variants in C3 (5.6%), C9 (6.7%), CFB (1.1%), and CFI (2.2%). This evidence concerns the gene C3 and age-related macular degeneration.